Clinical Data Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis PharmaTimesLead candidate ETD001 delivers significant lung function improvementRespiratoryRead full story pharminent May 12, 2026 (Last updated: May 16, 2026) PharmaTimes Lead candidate ETD001 delivers significant lung function improvement Respiratory Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cellular Intelligence scoops up Novo’s Parkinson’s therapyNext: 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
